Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophos…
Biotechnology
GB, London [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Roivant Sciences Ltd. (ROIV) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 38,935.34 | 13,377.10 | 619.41 | 356.01 | -1,101.12 | 0.00 | 12.8206 | 43.65 | -0.8417 | -20.0118 | -0.08 | -0.07 | 6.1551 | - - | ||
| Maximum | - - | - - | - - | 1,552,187.00 | 609,984.00 | 35,800.00 | 99,050.00 | 5,421.00 | 0.02 | 701.8537 | 2,849.43 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -164.8536 | -132.82 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0844 | - - | ||
| Roivant Sciences Ltd. ROIV | 12.53 | 0.71 6.01% | 11,361 vs. 6,203 | 9,121.00 | 28.00 | -151.00 | -108.00 | 576.00 | -0.1900 | -13.8534 | 0.0000 | 0.8475 | -5.2235 | -0.0253 | -0.0209 | 24.8109 | 727.00 | ||
| Revolution Medicines, Inc. RVMD | 56.75 | -0.03 -0.05% | 1,165 vs. 1,180 | 9,546.00 | 0.00 | -116.00 | -163.00 | -1,253.00 | -0.7000 | -11.2467 | 0.0000 | 0.0000 | 0.0000 | -0.0672 | -0.0608 | 18.1763 | 168.00 | ||
| Akero Therapeutics, Inc. AKRO | 32.73 | 1.53 4.90% | 824 vs. 554 | 2,284.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
| Prometheus Biosciences, Inc. RXDX | 199.92 | 0.18 0.09% | 1,787 vs. 1,217 | 9,558.00 | 1.00 | -40.00 | -40.00 | -371.00 | -0.8600 | -31.1524 | 0.0000 | 1.0000 | -36.9919 | -0.0586 | -0.0539 | 36.9012 | 47.00 | ||
| Blueprint Medicines Corporation BPMC | 94.15 | -2.47 -2.56% | 663 vs. 633 | 5,980.00 | 96.00 | 89.00 | -102.00 | -2,250.00 | 1.4500 | 16.6530 | 0.0000 | 0.9168 | 0.9274 | 0.2869 | 0.0858 | 3.4266 | 63.00 | ||
| Apellis Pharmaceuticals, Inc. APLS | 30.77 | 3.02 10.88% | 2,660 vs. 2,913 | 3,827.00 | 172.00 | -66.00 | -133.00 | -2,903.00 | -0.5400 | -27.6326 | 0.0000 | 0.8802 | -0.3855 | -0.2491 | -0.0798 | 2.7985 | 124.00 | ||
| Krystal Biotech, Inc. KRYS | 190.40 | 8.11 4.45% | 222 vs. 226 | 5,475.00 | 45.00 | 0.00 | 14.00 | -268.00 | 0.0300 | 1336.3467 | 0.0000 | 0.9465 | 0.0206 | 0.0012 | 0.0011 | 12.2870 | 28.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.